• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

European Pharmaceutical Review Extra

The latest blogs, views and comments on the Pharma world from the leading experts in the industry…

If you would like to submit an article for the website, contact Niamh Marriott.


Biosimilars create opportunities for sustainable cancer care

Posted on: 22 February 2017 | Author: Professor Josep Tabernero, Chair of the ESMO Cancer Medicines Working Group

Dr Josep Tabernero explains the benefits of biosimilars, showing how they can create sustainable, safe and affordable access to medicine globally...

UPDATE: The Cancer Drugs Fund

Posted on: 21 February 2017 | Author: Niamh Louise Marriott, Digital Editor

This page will be updated as the results from the Cancer Drugs Fund appraisal are announced by The National Institute of Health and Care Excellence (NICE).  Originally introduced in 2011, The Cancer Drugs Fund (CDF) was established by the coalition Government in order to provide a means by which NHS patients in England could get cancer […]

Driving business value from pharmaceutical serialisation

Posted on: 15 February 2017 | Author: Nicolás Giménez Stamminger, Manager IT Advisory, KPMG Switzerland

KMPG’s Nicolás Giménez Stamminger explains why serialisation is the solution to counterfeit medicines and how to implement a cost-effective serialisation strategy…


Looking for life sciences opportunities in a post-Brexit world

Posted on: 13 February 2017 | Author: Dr Penny Owen, Life Sciences Hub Wales

From government regulation to European trade, Life Sciences Hub Wales chairperson, Dr Penny Owen, looks ahead to the unknown of a post-Brexit world...


Why the Internet of Medical Things is the future of healthcare

Posted on: 10 February 2017 | Author: Niamh Marriott, Digital Editor

We caught up with Nexeon’s CEO, Will Rosellini, to talk about the Internet of Medical Things - the dangers, the benefits and what the future holds...


2017 pipelines: AstraZeneca – another challenging year

Posted on: 8 February 2017 | Author: Brian White and Paul Taylor, Healthcare analysts, Cantor Fitzgerald Europe

Healthcare analysts predict another difficult year ahead for the pharmaceutical giant, after 2016 was beset with competitive and pricing pressures...

Serialisation and Traceability: Knowing your implementation and expenditures

Posted on: 6 February 2017 | Author: Pasi Kemppainen, Executive Consultant, Pharma Serialisation and Traceability

Pharma serialisation and traceability expert, Pasi Kemppainen, gives us his insights on how to ensure a future-proof and cost-effective strategy

The Top 21…wealthiest pharma companies

Posted on: 6 February 2017 | Author: Niamh Marriott, Digital Editor

Find out who made it to the top of our list of richest pharma companies...

Democratising clinical genomics while protecting data privacy 

Posted on: 1 February 2017 | Author: Jurgi Camblong (CEO, Sophia Genetics)

Sophia Genetics co-founder and CEO, Jurgi Camblong, tackles issues of privacy and security for healthcare patient data...

Transforming healthcare in the era of Trump: An opportunity to disrupt

Posted on: 20 January 2017 | Author: Stephen Klasko, President and CEO, Thomas Jefferson University and Jefferson Health; Editor-in-Chief, Healthcare Transformation

With Trump’s rule imminent, President and CEO of Thomas Jefferson University, Stephen Klasko, puts forth a manifesto for healthcare reform, disruption and change…


The Good, the Bad, and the Donald: what Pharma can expect from 2017

Posted on: 11 January 2017 | Author: Niamh Marriott, Digital Editor

From an orphan drug sales boom to uncharted political landscapes, the CPhI Worldwide expert panel predict pharma’s biggest opportunities and threats in 2017.


How Trump’s victory will impact Life Sciences

Posted on: 13 December 2016 | Author: Alex Pye and Mark Brewer, Life Sciences analysts, finnCap

Threats to immediately end Obamacare? Import cheaper drugs from overseas? Analysts Alex Pye and Mark Brewer look to the facts for Trump's pharma impact...


Webinar: NIR Spectroscopy for Assessing Blend Uniformity in the Pharmaceutical IndustryLEARN MORE
+ +